Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for $8.00 per share in cash upfront, with an additional $2.00 per share contingent value right tied to VG-3927's first commercial sale.
Alzamend Neuro partners with Tesla Dynamic Coils BV to develop a groundbreaking MRI head coil for measuring brain lithium levels across five Phase II clinical trials at Massachusetts General Hospital.
Vigil Neuroscience reports positive Phase 1 data for VG-3927, an oral TREM2 agonist, showing a favorable safety profile in healthy adults and Alzheimer's patients.
OST-HER2 demonstrated a statistically significant 12-month event-free survival (EFS) rate of 33.3% compared to 20% in historical controls for recurrent, fully resected osteosarcoma with lung metastases.
Alector anticipates topline data from the Phase 3 INFRONT-3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation (FTD-GRN) by Q4 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.